Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥6.3bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥13.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥111m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥157m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥108m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥195m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥182m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥185m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥10.6bnat 2024-09-30Cons.Assets
Total assets¥9.8bnat 2024-03-31Cons.Assets
Total assets¥10.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥3.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥5.8bnat 2024-09-30Cons.Net assets
Net assets / equity¥6.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.3bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥2.5bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥2.2bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥421m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥392m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥175m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥281m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥379m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥343m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-10.972024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.242023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio53.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio60.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥114m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥806m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥803m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥189m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥45,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥192m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥3m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Number of shares heldCurrentQuarterInstant_No2MajorShareholdersMember202900
Shareholding ratioCurrentQuarterInstant_No2MajorShareholdersMember0.0121
Number of shares heldCurrentQuarterInstant_No3MajorShareholdersMember183500
Shareholding ratioCurrentQuarterInstant_No3MajorShareholdersMember0.0110
Number of shares heldCurrentQuarterInstant_No4MajorShareholdersMember173000
Shareholding ratioCurrentQuarterInstant_No4MajorShareholdersMember0.0103
Number of shares heldCurrentQuarterInstant_No5MajorShareholdersMember160200
Shareholding ratioCurrentQuarterInstant_No5MajorShareholdersMember0.0096
Number of shares heldCurrentQuarterInstant_No6MajorShareholdersMember150000
Shareholding ratioCurrentQuarterInstant_No6MajorShareholdersMember0.0090
Number of shares heldCurrentQuarterInstant_No7MajorShareholdersMember136900
Shareholding ratioCurrentQuarterInstant_No7MajorShareholdersMember0.0082
Number of shares heldCurrentQuarterInstant_No8MajorShareholdersMember120700
Shareholding ratioCurrentQuarterInstant_No8MajorShareholdersMember0.0072
Number of shares heldCurrentQuarterInstant_No9MajorShareholdersMember113800
Shareholding ratioCurrentQuarterInstant_No9MajorShareholdersMember0.0068
Number of shares heldCurrentQuarterInstant_No10MajorShareholdersMember111200
Shareholding ratioCurrentQuarterInstant_No10MajorShareholdersMember0.0066
Number of shares heldCurrentQuarterInstant1793411
Shareholding ratioCurrentQuarterInstant0.1076
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember345900
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember16645200
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember166452
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember8041
Number of shares issued shares voting rightsCurrentQuarterInstant16999141
Number of voting rights issued shares voting rightsCurrentQuarterInstant166452
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member345900
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member345900
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0203
Number of shares held in own name treasury shares etcCurrentQuarterInstant345900
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant345900
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0203
Cash and depositsPrior1YearInstant2478229000JPY
Cash and depositsCurrentQuarterInstant2266344000JPY
Notes and accounts receivable trade and contract assetsPrior1YearInstant1342735000JPY
Notes and accounts receivable trade and contract assetsCurrentQuarterInstant1192647000JPY
Electronically recorded monetary claims operating caPrior1YearInstant-JPY
Electronically recorded monetary claims operating caCurrentQuarterInstant392515000JPY
Merchandise and finished goodsPrior1YearInstant1592915000JPY
Merchandise and finished goodsCurrentQuarterInstant1605887000JPY
Work in processPrior1YearInstant507606000JPY
Work in processCurrentQuarterInstant785712000JPY
Raw materials and suppliesPrior1YearInstant127179000JPY
Raw materials and suppliesCurrentQuarterInstant110512000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass